Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.
The Conversation logo

Emerging from vague familiarity into the spotlight as the only route out of the pandemic, vaccines have become an everyday topic of conversation. Most of us now understand the principle of vaccination: our immune system is presented with a part of a pathogen and instructed to create a lasting immune response to it, safeguarding us against future infection. But few people know about vaccine ingredients that can be essential for inducing a potent immune response: adjuvants.

Named from the Latin “adiuvare” meaning “to help”, adjuvants have been lending a helping hand to vaccinologists for many decades. Yet a lack of a clear understanding of how they work has tainted their reputation, leading to epithets such as “alchemy” and “the immunologist’s dirty secret”.

Read the full article on The Conversation website, written by Dr Anita Milicic, Jenner Institute, Nuffield Department of Medicine.

Oxford is a subscribing member of The ConversationFind out how you can write for The Conversation.

Similar stories

Oxford vaccine reaches one billion doses released

The University of Oxford’s and our partners AstraZeneca have today announced that one billion doses of the ChAdOx1 nCov-19 coronavirus vaccine have been released, to more than 170 countries, marking a key milestone as part of the University and AstraZeneca’s joint vision to make the available to the world, on a not-for-profit basis for the world during the pandemic, and in perpetuity for low- and middle-income countries.

Research programme tackling COVID-19 variants of concern receives funding boost

A gift from the Red Avenue Foundation will enable the expansion of a major research programme aimed at rapidly identifying and interrogating emerging COVID-19 variants.

Phase I trial begins of new vaccine against the Plague

Researchers at the University of Oxford today launched a Phase 1 trial to test a new vaccine against plague.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Treatment choice for rotator cuff disorders could create efficiency and savings for the NHS

A trial that evaluated the clinical and cost effectiveness of physiotherapy treatments for rotator cuff disorders suggests cost savings can be made while maintaining positive patient outcomes.